Search
for
Sort by
Research 181–210 of 524
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment
- Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Single-Nucleus and Bulk RNA Sequencing Reveals the Involvement of Natural Killer and CD8+ T Cells in the Progression of Androgenetic Alopecia
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- European expert consensus statement on the systemic treatment of alopecia areata
- Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
- JAK inhibitors in dermatology: The promise of a new drug class
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Under Development JAK Inhibitors for Dermatologic Diseases
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options